

**CORRIGENDUM**

**Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial**

Ann Oncol 2019; 30: 1992–2003

N. W. Clarke<sup>1\*</sup>, A. Ali<sup>2</sup>, F. C. Ingleby<sup>3,4</sup>, A. Hoyle<sup>1</sup>, C. L. Amos<sup>3</sup>, G. Attard<sup>5</sup>, C. D. Brawley<sup>3</sup>, J. Calvert<sup>3</sup>, S. Chowdhury<sup>6</sup>, A. Cook<sup>3</sup>, W. Cross<sup>7</sup>, D. P. Dearnaley<sup>8</sup>, H. Douis<sup>9</sup>, D. Gilbert<sup>3</sup>, S. Gillissen<sup>10</sup>, R. J. Jones<sup>11</sup>, R. E. Langley<sup>3</sup>, A. MacNair<sup>3</sup>, Z. Malik<sup>12</sup>, M. D. Mason<sup>13</sup>, D. Matheson<sup>14</sup>, R. Millman<sup>3</sup>, C. C. Parker<sup>8,15</sup>, A. W. S. Ritchie<sup>3</sup>, H. Rush<sup>3</sup>, J. M. Russell<sup>16</sup>, J. Brown<sup>17</sup>, S. Beesley<sup>18</sup>, A. Birtle<sup>19</sup>, L. Capaldi<sup>20</sup>, J. Gale<sup>21</sup>, S. Gibbs<sup>22</sup>, A. Lydon<sup>23</sup>, A. Nikapota<sup>24</sup>, A. Omlin<sup>25</sup>, J. M. O’Sullivan<sup>26</sup>, O. Parikh<sup>27</sup>, A. Protheroe<sup>28</sup>, S. Rudman<sup>6</sup>, N. N. Srihari<sup>29</sup>, M. Simms<sup>30</sup>, J. S. Tanguay<sup>31</sup>, S. Tolan<sup>12</sup>, J. Wagstaff<sup>32</sup>, J. Wallace<sup>11</sup>, J. Wylie<sup>33</sup>, A. Zarkar<sup>34</sup>, M. R. Sydes<sup>3</sup>, M. K. B. Parmar<sup>3</sup> & N. D. James<sup>35</sup>, the STAMPEDE investigators

<sup>1</sup>Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester; <sup>2</sup>Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester; <sup>3</sup>MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; <sup>4</sup>London School of Hygiene and Tropical Medicine, London; <sup>5</sup>UCL Cancer Institute, London; <sup>6</sup>Guy’s and Saint Thomas’ NHS Foundation Trust, London; <sup>7</sup>St James University Hospital, Leeds; <sup>8</sup>Institute of Cancer Research, Sutton-London; <sup>9</sup>Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham; <sup>10</sup>Division of Cancer Sciences, The University of Manchester, Manchester; <sup>11</sup>eatson West of Scotland Cancer Centre, University of Glasgow, Glasgow; <sup>12</sup>The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; <sup>13</sup>Cardiff University, Cardiff; <sup>14</sup>Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton; <sup>15</sup>Royal Marsden NHS Foundation Trust, London; <sup>16</sup>Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow; <sup>17</sup>University of Sheffield, Sheffield; <sup>18</sup>Kent Oncology Centre, Maidstone; <sup>19</sup>Lancashire Teaching Hospitals NHS Foundation Trust, Preston; <sup>20</sup>Worcestershire Acute Hospitals NHS Trust, Worcester; <sup>21</sup>Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth; <sup>22</sup>Queen’s Hospital, Romford; <sup>23</sup>Torbay and South Devon NHS Foundation Trust, Torbay; <sup>24</sup>Sussex Cancer Centre, Brighton; <sup>25</sup>Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland; <sup>26</sup>Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast; <sup>27</sup>East Lancashire Hospitals NHS Trust, Blackburn; <sup>28</sup>Oxford University Hospitals NHS Foundation Trust, Oxford; <sup>29</sup>Shrewsbury and Telford Hospital NHS Trust, Shrewsbury; <sup>30</sup>Hull and East Yorkshire Hospitals NHS Trust, Hull; <sup>31</sup>Velindre Cancer Centre, Cardiff; <sup>32</sup>Swansea University College of Medicine, Swansea; <sup>33</sup>The Christie NHS Foundation Trust, Manchester; <sup>34</sup>Heartlands Hospital, Birmingham; <sup>35</sup>Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.

DOI of original article: <https://doi.org/10.1093/annonc/mdz396>

\*Correspondence to: Prof. Noel W. Clarke, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel: +44 161 446 3364; Fax: +44 161 446 3365

E-mail: [noel.clarke@christie.nhs.uk](mailto:noel.clarke@christie.nhs.uk) (N. W. Clarke).

0923-7534/© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).